Prostate Cell News Volume 5.41 | Oct 31 2014

Nuclear iASPP May Facilitate Prostate Cancer Progression
Researchers identified inhibitor of apoptosis-stimulating protein of p53 (iASPP), a common cellular regulator of p53 and p63, as an important player of prostate cancer progression. [Cell Death Dis] Full Article

ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer
Genomic analysis of ERG siRNA-treated prostate cells harboring the endogenous TMPRSS2-ERG fusion revealed an inverse relationship between ERG and Annexin A2 (ANXA2) expression at both the RNA and protein level. ERG overexpression disrupted ANXA2 mediated cell polarity and promoted epithelial mesenchymal transition by inhibiting CDC42 and RHOA, and by activating cofilin. [Mol Cancer Res] Abstract

HIF-1alpha Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
To further analyze the consequences of hypoxic upregulation on stem cell proliferation and hypoxia-inducible factor 1alpha signaling, cancer stem cells subpopulations from murine TRAMP-C1 cells as well as from a human prostate cancer cell line were isolated and characterized. [Mol Cancer Res] Abstract

N-3 Polyunsaturated Fatty Acids Inhibit IFN-γ-Induced IL-18 Binding Protein Production by Prostate Cancer Cells
Investigators demonstrate that n-3 polyunsaturated fatty acids treatment significantly reduced interferon (IFN)-γ-induced IL-18BP production by DU-145 and PC-3 prostate cancer cells by inhibiting IL-18BP mRNA expression and was associated with a reduction in IFN-γ receptor expression. [Cancer Immunol Immunother] Abstract

Epithelial-Mesenchymal Transition in Prostate Cancer Is Associated with Quantifiable Changes in Nuclear Structure
Researchers determined whether epithelial and mesenchymal prostate cancer cells have different nuclear morphology. Murine tibia injections of epithelial PC3 and mesenchymal PC3 prostate cancer cells were processed and stained with H&E. [Prostate] Abstract

Nobiletin Suppresses Cell Viability through AKT Pathways in PC-3 and DU-145 Prostate Cancer Cells
Scientists investigated the effects of nobiletin in prostate cancer cell lines PC-3 and DU-145. Data showed that nobiletin decreased cell viability in both prostate cell lines, with a greater reduction in viability in PC-3 cells. [BMC Pharmacol Toxicol] Full Article

CLINICAL RESEARCH

Efficacy and Safety of Radium-223 Dichloride in Patients with Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases, with or without Previous Docetaxel Use: A Prespecified Subgroup Analysis from the Randomized, Double-Blind, Phase III ALSYMPCA Trial
Researchers analyzed a prespecified subgroup from ALSYMPCA to assess the effect of previous docetaxel use on the efficacy and safety of radium-223. [Lancet Oncol] Abstract

^99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer
Under an exploratory investigational new drug, using a cross-over design, the authors compared the pharmacokinetics, biodistribution, and tumor uptake of ^99mTc-MIP-1404 and ^99mTc-MIP-1405 in six healthy men and six men with radiographic evidence of metastatic prostate cancer. [J Nucl Med] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

TapImmune Provides Update on PolyStart™ Vaccine Platform Applicable to Cancer and Infectious Disease
TapImmune, Inc. provided an update on the status of its PolyStart™ vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus. [TapImmune, Inc.] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Senior Research Associate – Nanomedicine (University of East Anglia)

Postdoctoral Fellow – Role of Deregulated PTEN/FOXO1 Pathway in Prostate Cancer (Mayo Clinic)

Postdoctoral Fellow – Oncology (Johnson & Johnson Pharmaceutical Research & Development)

Postdoctoral Fellow – Prognostic Biomarkers for Prostate Cancer (McGill University)

Physician Scientist – Prostate Cancer Genomics (University of Chicago)

Tenure Track Position – Cancer Biology (Wake Forest Baptist Medical Center)

Postdoctoral Position – Bioinformatics for Prostate Cancer (CRUK Manchester Institute)

Postdoctoral Fellows and Graduate Student Positions (Vancouver Prostate Centre)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.